AssayIndex
HYB cross-section

HYB by compound

HYB records split by compound, with the index-wide comparison for the same compound beside each one. 25 compounds, 241 records. Cells below n=3 print their raw values instead of a median.

25 compounds241 records
CompoundClassReportsHYB median %Index median %Δ (pp)SpecPass %
TirzepatideIncretin2998.7098.55+0.1597.0100
SemaglutideIncretin2498.9298.89+0.0397.0100
RetatrutideIncretin2198.3598.37-0.0296.5100
BPC-157Tissue-repair1699.3999.16+0.2398.0100
CJC-1295 (no DAC)Growth-hormone1699.2699.09+0.1798.0100
TriptorelinHypothalamic1299.4699.41+0.0598.5100
IGF-1 LR3Growth-hormone1298.9098.28+0.6295.0100
L-Glutathione (reduced)Short1299.3999.33+0.0698.5100
GHRP-2Growth-hormone1299.8699.28+0.5899.0100
MOTS-cMetabolic1199.5499.13+0.4198.0100
HexarelinGrowth-hormone1199.9399.59+0.3499.0100
MGFGrowth-hormone999.7499.29+0.4597.5100
ExenatideIncretin998.7498.98-0.2498.0100
ARA-290Tissue-repair899.3499.42-0.0898.0100
SS-31 (Elamipretide)Metabolic6 n=699.6899.53+0.1598.5100
Enclomiphene citrateNon-peptide6 n=699.6699.44+0.2198.5100
DihexaNeuroactive6 n=699.6499.63+0.0198.5100
MK-677 (Ibutamoren mesylate)Non-peptide5 n=599.8799.49+0.3898.5100
EpitalonShort4 n=499.8099.56+0.2499.0100
Melanotan IIMelanocortin-receptor3 n=399.4699.42+0.0498.5100
PT-141 (Bremelanotide)Melanocortin-receptor3 n=399.2799.38-0.1198.5100
KPVTissue-repair2 n=2n<399.6499.0100
GHRP-6Growth-hormone2 n=2n<399.5499.0100
CJC-1295 with DACGrowth-hormone1 n=1n<398.9597.5100
SelankNeuroactive1 n=1n<399.5999.0100
97.798.198.598.999.399.7100.1TirzepatideTirzepatide: Q1 98.31, median 98.70, Q3 99.10, n=29n=29SemaglutideSemaglutide: Q1 98.71, median 98.92, Q3 99.34, n=24n=24RetatrutideRetatrutide: Q1 98.22, median 98.35, Q3 98.66, n=21outlier 99.58n=21BPC-157BPC-157: Q1 99.26, median 99.39, Q3 99.59, n=16n=16CJC-1295 (no DAC)CJC-1295 (no DAC): Q1 99.18, median 99.26, Q3 99.49, n=16outlier 98.45n=16TriptorelinTriptorelin: Q1 99.40, median 99.46, Q3 99.52, n=12outlier 99.93outlier 99.93n=12IGF-1 LR3IGF-1 LR3: Q1 98.75, median 98.90, Q3 99.22, n=12outlier 98.01n=12L-Glutathione (reduce…L-Glutathione (reduce…: Q1 99.34, median 99.39, Q3 99.52, n=12outlier 99.82n=12GHRP-2GHRP-2: Q1 99.80, median 99.86, Q3 99.93, n=12outlier 99.57n=12MOTS-cMOTS-c: Q1 99.33, median 99.54, Q3 99.77, n=11outlier 98.29n=11HexarelinHexarelin: Q1 99.78, median 99.93, Q3 99.93, n=11outlier 99.35n=11MGFMGF: Q1 99.72, median 99.74, Q3 99.93, n=9n=9ExenatideExenatide: Q1 98.70, median 98.74, Q3 98.83, n=9outlier 98.40outlier 99.04outlier 99.93n=9ARA-290ARA-290: Q1 99.30, median 99.34, Q3 99.44, n=8outlier 99.66outlier 99.93n=8 Purity (% area)
Figure. Distribution per compound where n ≥ 4. Rows are ordered by coverage, not by result.

Which of these lines HYB actually stocks

Coverage here reflects what has been submitted to the index, not what is on the catalogue. Shenzhen Hybio Pharmaceutical Co., Ltd. lists considerably more than the 25 compounds above. Of those 25, 17 have been seen arriving from a domestic warehouse rather than as a cross-border consignment — that is the whole of what the index can say about which lines are held in regional stock, and it is a record of what was submitted, not a stock position. The catalogue and the current stock position are on the supplier's own site.

Browse the HYB catalogue at hybiopharmaceutical.com →